Clinical TrialNeuroimaging & Brain MeasuresLSDLSDPlaceboCompleted

LSD-Perceptual-Choice-Study (LUCY)

This randomized, double-blinded, crossover trial (n=30) aims to characterise the effects of low doses of LSD on behavioural and neural indicators of feedback and feedforward signalling in perceptual decision-making.

Target Enrollment
30 participants
Study Type
Phase NA interventional
Design
Randomized, double Blind

Detailed Description

Randomized, double-blind, crossover pharmacological challenge in healthy volunteers comparing 10 µg, 20 µg LSD and placebo across three 5-hour sessions with at least 7 days washout.

Participants perform multiple perceptual decision-making tasks with concurrent EEG to probe behavioural and neural indices of prior beliefs and evidence processing; continuous supervision until ~4.5 hours post-administration.

Study Protocol

Preparation

sessions

Dosing

3 sessions
300 min each

Integration

sessions

Study Arms & Interventions

LSD 10 µg

experimental

Single low-dose LSD session (10 µg total) as part of 3-period crossover.

Interventions

  • LSD10 µg
    via Oral• single dose

    Administered as two 1 ml vials (10 µg + 0 µg) to yield 10 µg total; vials in 20% EtOH; given 0.5 h after session start.

LSD 20 µg

experimental

Single low-dose LSD session (20 µg total) as part of 3-period crossover.

Interventions

  • LSD20 µg
    via Oral• single dose

    Administered as two 1 ml vials (10 µg + 10 µg) to yield 20 µg total; vials in 20% EtOH; given 0.5 h after session start.

Placebo

inactive

Placebo session (0 µg) as part of 3-period crossover.

Interventions

  • Placebo0 µg
    via Oral• single dose

    Two placebo vials (0 µg each) in 20% EtOH; given 0.5 h after session start.

Participants

Ages
18 – 65
Sexes
Male & Female

Inclusion Criteria

  • Willingness to adhere to the study protocol and sign the consent form
  • ≥ 18 and ≤ 65 years of age at Screening
  • Body mass index 18-29
  • Fluent understanding of German
  • Normal or corrected-to-normal vision
  • Willingness to not operate a traffic vehicle or heavy machinery 24 hours after substance administration
  • Willingness to refrain from taking illicit psychoactive substances, including cannabis, for the duration of the study
  • Willingness to not consume more than one alcoholic standard drink the night before the study sessions and not consume alcohol for 24 h after each study session
  • Willingness to abstain from xanthine-based liquids from the evenings prior to the study sessions and during the sessions
  • Willingness to use effective birth-control throughout the study duration
  • Adequate task performance in the decision-making tasks during a practice session in the screening visit

Exclusion Criteria

  • Recent (<30 days) or current participation in another clinical trial
  • Women that are pregnant, nursing, or planning to become pregnant during the study period
  • Current use of contraindicated/psychoactive medications or illicit drugs
  • Lifetime use of classical psychedelics more than 20 times, or any time within the previous two months
  • Consumption of >5 cigarettes per day or >20 alcoholic standard drinks per week
  • Severe chronic or acute medical condition
  • Hypertension (>140/90 mmHg) or hypotension (<85mmHg systolic)
  • Current or lifetime major mental health disorder
  • Personal or family (first-degree) history of a primary psychotic disorder

Study Details

Locations

University Psychiatric Clinics Basel — Basel, Switzerland

Your Library